H.C. Wainwright analyst Brandon Folkes assumed coverage of Enanta (ENTA) with a Buy rating and $20 price target The shares offer a favorable risk/reward at current share levels, driven by the company’s upcoming clinical catalysts and diversified pipeline in virology and immunology, the analyst tells investors in a research note. The firm likes the stock into the respiratory syncytial virus Phase 2 data readout.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: